ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

GANX vs SER // RSI-14 & 200D SMA MOMENTUM

Gain Therapeutics Inc. (NASDAQ) VS. Serina Therapeutics Inc. (NYSE) • 15-METRIC TALLY: GANX 2 — SER 1
▲ RSI-14 & 200D SMA MOMENTUM LEADER: SER
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GANX VS. SER) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC GANX SER SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 132.10% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 3/9 +1.00 GANX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 31.0 52.3 -21.30 SER /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $49.3M $49.3M $40.4K GANX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR GANX REV SER REV GANX GROSS % SER GROSS % GANX FCF SER FCF
FY 2025 $52.4M $130.0K — — -$18.5M -$18.0M
FY 2024 $57.0M $56.0K — — -$18.9M -$17.2M
FY 2023 $55.2K $3.2M — — -$18.9M -$2.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GANX // BETA —
SER // BETA —